Cargando…

Hsp90 Inhibitor STA9090 induced VPS35 related extracellular vesicle release and metastasis in hepatocellular carcinoma

Heat shock protein 90 (Hsp90) has been an important therapeutic target for cancer therapy for decades. Unexpectedly, the monotherapy of N-terminal Hsp90 inhibitor STA9090 related clinical trials halted in phase III, and metastases were reported in animal models with the treatment of N-terminal Hsp90...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Wenchong, Zhang, Jinxin, Liu, Lixia, Liang, Manfeng, Li, Jieyou, Deng, Zihao, Zheng, Zhenming, Deng, Yaotang, Liu, Chenyang, Li, Yan, Xie, Guantai, Zhang, Jiajie, Zou, Fei, Chen, Xuemei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493061/ https://www.ncbi.nlm.nih.gov/pubmed/36137350 http://dx.doi.org/10.1016/j.tranon.2022.101502

Ejemplares similares

HSP90 C-terminal domain inhibition promotes VDAC1 oligomerization via decreasing K274 mono-ubiquitination in Hepatocellular Carcinoma
por: Zhang, Jinxin, et al.
Publicado: (2023)

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
por: Proia, David A., et al.
Publicado: (2011)

HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma
por: Guan, Liuliu, et al.
Publicado: (2020)

STA9090 as a Potential Therapeutic Agent for Liver Fibrosis by Modulating the HSP90/TβRII/Proteasome Interplay: Novel Insights from In Vitro and In Vivo Investigations
por: Mohammed, Osama A., et al.
Publicado: (2023)

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
por: Goldman, Jonathan W, et al.
Publicado: (2013)

Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
por: London, Cheryl A., et al.
Publicado: (2011)

Extracellular Hsp90α, which participates in vascular inflammation, is a novel serum predictor of atherosclerosis in type 2 diabetes
por: Ding, Xinyi, et al.
Publicado: (2022)

VPS35 leaves endosomes lost in transition
por: Leslie, Mitch
Publicado: (2011)

Screening for VPS35 mutations in Parkinson's disease
por: Sheerin, Una-Marie, et al.
Publicado: (2012)

VPS35, the Retromer Complex and Parkinson’s Disease
por: Williams, Erin T., et al.
Publicado: (2017)

STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma
por: Heske, Christine M., et al.
Publicado: (2016)

Endosome to Golgi Retrieval of the Vacuolar Protein Sorting Receptor, Vps10p, Requires the Function of the VPS29, VPS30, and VPS35 Gene Products
por: Seaman, Matthew N.J., et al.
Publicado: (1997)

VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology
por: Wen, Lei, et al.
Publicado: (2011)

In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila
por: Wang, Hua-shan, et al.
Publicado: (2014)

VPS35 regulates tau phosphorylation and neuropathology in tauopathy
por: Vagnozzi, Alana N., et al.
Publicado: (2021)

Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma
por: Wen, Ying, et al.
Publicado: (2018)

The Role of HSP90 Inhibitors in the Treatment of Cardiovascular Diseases
por: Qi, Shiyu, et al.
Publicado: (2022)

Depletion of VPS35 attenuates metastasis of hepatocellular carcinoma by restraining the Wnt/PCP signaling pathway
por: Liu, Yi, et al.
Publicado: (2020)

VPS35 Parkinson mutation impairs autophagy via WASH
por: Zavodszky, Eszter, et al.
Publicado: (2014)

VPS35 depletion does not impair presynaptic structure and function
por: Vazquez-Sanchez, Sonia, et al.
Publicado: (2018)

VPS35, the core component of the retromer complex, and Parkinson's disease
por: Luo, Ai‐Di, et al.
Publicado: (2021)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

Hsp-90 and the biology of nematodes
por: Him, Nik AIIN, et al.
Publicado: (2009)

Mechanisms of Hsp90 regulation
por: Prodromou, Chrisostomos
Publicado: (2016)

Regulatory Mechanisms of Hsp90
por: Prodromou, Chrisostomos
Publicado: (2017)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Role of HSP90 in Cancer
por: Birbo, Bereket, et al.
Publicado: (2021)

Organismal Roles of Hsp90
por: van Oosten-Hawle, Patricija
Publicado: (2023)

Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration
por: Tsika, Elpida, et al.
Publicado: (2014)

The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
por: Chang, Cheng, et al.
Publicado: (2023)

STA-Distal ACA Bypass Using a Contralateral STA Interposition Graft for Symptomatic ACA Stenosis
por: Hwang, Yoon Ha, et al.
Publicado: (2018)

Time trends in the outcome of lung cancer management: a study of 9,090 cases diagnosed in the Mersey Region, 1974-86.
por: Watkin, S. W., et al.
Publicado: (1990)

Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
por: Park, Sangkyu, et al.
Publicado: (2019)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

Expression of Low Level of VPS35-mCherry Fusion Protein Diminishes Vps35 Depletion Induced Neuron Terminal Differentiation Deficits and Neurodegenerative Pathology, and Prevents Neonatal Death
por: Zhao, Yang, et al.
Publicado: (2021)

The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
por: Lackie, Rachel E., et al.
Publicado: (2017)

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
por: Li, Ting, et al.
Publicado: (2018)

A deletion in the STA1 promoter determines maltotriose and starch utilization in STA1+ Saccharomyces cerevisiae strains
por: Krogerus, Kristoffer, et al.
Publicado: (2019)

Pathogenic Mutation in VPS35 Impairs Its Protection against MPP(+) Cytotoxicity
por: Bi, Fangfang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uaa7qr2qcd71cbaiikt326c0qq